Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

November 30, 2015

JOHANNESBURG/HARARE—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today warned that lifesaving antiretroviral medicines (ARVs) are routinely not making their way to patients in sub-Saharan Africa, most often despite sufficient stocks already being present in countries, and called for urgent improvements in ARV supply chains in the region.

October 28, 2015

JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country.

September 30, 2015

GENEVA/JOHANNESBURG—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières today applauded the new guidelines from the World Health Organization (WHO) that all people be offered antiretroviral treatment immediately after testing positive for HIV. But MSF warned that turning this new recommendation into reality would require dramatically increased support from donors and governments.

July 23, 2015

VANCOUVER—At the International AIDS Society (IAS) Conference today, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) warned that middle-income countries (MICs), which will be home to 70 percent of people living with HIV by 2020, face increasing threats to their ability to access affordable generic medicines, which are crucial to countries’ ability to reach the global UNAIDS 90/90/90* targets.

July 21, 2015

New MSF report surveying lay counselor policies across eight countries highlights major weaknesses for adherence support

July 20, 2015

Vancouver, July 20, 2015—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières Borders (MSF) applauded the results of the Strategic Timing of Antiretroviral Treatment (START) trial, released today at the International AIDS Society Conference (IAS) in Vancouver, showing that immediate treatment is beneficial for individuals regardless of the status of their immune system.

February 25, 2015

SEATTLE/NEW YORK—Among individuals not receiving antiretroviral treatment, men had twice the level of HIV virus in their blood as women at the same stage in the disease, according to one of the major findings of a three-country Doctors Without Borders/Médecins Sans Frontières (MSF) population survey presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle Wednesday.

November 24, 2014

JOHANNESBURG/NEW YORK—The recent call by UNAIDS to “close the gap”around access to HIV services will not be met unless the delivery of antiretroviral treatment (ARV) is radically reshaped into community-led approaches that adapt to the realities of those living with HIV, said the international medical humanitarian organization Doctors Without Borders/Médecins sans Frontières (MSF) ahead of World Aids Day, December 1.

July 21, 2014

 

MELBOURNE/NEW YORKHigh prices continue to represent a major barrier to affordable access of both new HIV medicines and viral load testing—which is the best way to monitor whether treatment is working—according to two reports released today by international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF). 

March 06, 2014

Boston/New York, March 6, 2014—Two new studies released today by Epicentre,the research arm of the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) at CROI, the Conference on Retroviruses and Opportunistic Infections, point to reductions in new HIV infections in areas where HIV treatment has been greatly expanded. The studies are some of the first to look at large-scale antiretroviral therapy (ART) rollout in real-world high-HIV-burden settings in sub-Saharan Africa, and its possible impact on reducing new infections.

Pages